Abstract: Hepatic steatosis and insulin resistance are among the most prevalent metabolic disorders and tightly associated with obesity and type 2 diabetes. However, underlying mechanism linking obesity to hepatic lipid accumulation and insulin resistance are incompletely understood. Glycoprotein 130 (gp130) is the common signal transducer of all interleukin 6 (IL-6) cytokines. Herein, we provide evidence that gp130-mediated adipose tissue lipolysis promotes hepatic steatosis and insulin resistance. In obese mice, adipocyte-specific gp130 deletion reduced basal lipolysis and enhanced insulin's ability to suppress lipolysis from mesenteric but not epididymal adipocytes. Consistently, free fatty acid levels were reduced in portal but not in systemic circulation of obese knockout mice. Importantly, adipocyte-specific gp130 knockout mice were protected from high fat diet (HFD)-induced hepatic steatosis as well as insulin resistance. In humans, omental but not subcutaneous IL-6 mRNA expression correlated positively with liver lipid accumulation (r=0.31; p<0.05) and negatively with euglycemic clamp glucose infusion rate (r=-0.28; p<0.05). Our results demonstrate that IL-6 cytokine-induced lipolysis may be restricted to mesenteric WAT and that it contributes to hepatic insulin resistance and steatosis. Therefore, blocking IL-6 cytokine signaling in (mesenteric) adipocytes may be a novel approach to blunt detrimental fat-liver crosstalk in obesity. adipocytes may be a novel approach to blunt detrimental fat-liver crosstalk in obesity.
Introduction
The prevalence of obesity and associated diseases such as insulin resistance and hepatic steatosis are increasing to epidemic proportions (1) . Yet, underlying pathological mechanisms are not fully understood. Although there is evidence that interleukin-6 (IL-6) may contribute to the development of fatty liver disease and hepatic insulin resistance, its exact role in the pathogenesis of these disorders is the subject of intense debate (2) (3) (4) (5) . IL-6 is secreted by different cells and tissues such as adipocytes, immune cells and skeletal muscle thereby modulating metabolism under both physiological and pathophysiological conditions (2; 6). To activate its intracellular signaling pathways, IL-6 either binds to its membrane-bound receptor (mIL-6R; classic signaling) or to its soluble receptor (sIL-6; trans-signaling pathway). Of note, mIL-6R is expressed in the liver and immune cells while it is absent in adipocytes (7) . In turn, this ligand/receptor complex associates with a homodimer of glycoprotein 130 (gp130), which is a common signal transducer protein of all IL-6 cytokines (8; 9). Subsequently, the JAK/STAT and the ERK1/2 pathway are activated (9; 10).
In the liver, chronically elevated circulating IL-6 levels were proposed to induce insulin resistance and inflammation in mice (11; 12) . In contrast, a recent study proposed the opposite since it found IL-6 to reduce inflammation and to improve insulin sensitivity in the liver (13) . Therefore, the hepatic derangements associated with elevated IL-6 levels as observed in the former studies (11; 12) may be mediated via an indirect effect of IL-6, for example through induction of adipose tissue lipolysis. Indeed, IL-6 was shown to induce lipolysis in vivo and in vitro (14; 15) and a recent publication suggested that IL-6 promotes hepatic insulin resistance indirectly through increased free fatty acid (FFA) release from adipose tissue in rodents (16) . Of note, obesity-induced IL-4 6 increase was higher in mesenteric fat compared to other adipose depots (17; 18) suggesting that IL-6-induced adipose tissue lipolysis may play a distinct role in visceral fat.
In the present study, we sought to determine whether (i) mesenteric adipose tissue is more sensitive to IL-6 -induced lipolysis than epididymidal fat and whether (ii) IL-6-induced FFA-release from (mesenteric) fat contributes to obesity-associated hepatic steatosis and insulin resistance making use of adipocyte-specific gp130 depleted mice.
Research Design and Methods

Determination of total liver fat and adipose tissue IL-6 mRNA expression in humans
IL-6 mRNA expression was measured in abdominal omental and subcutaneous adipose tissue (AT) samples obtained in parallel from 63 men (n = 34) and women (n = 29) who underwent open abdominal surgery for Roux-en-Y bypass, sleeve gastrectomy, explorative laparotomy or elective cholecystectomy. Liver and AT biopsies was taken during surgery, immediately snap-frozen in liquid nitrogen, and stored at −80°C until further preparations. Measurement of total body and liver fat, tissue sample handling and analysis of blood samples including measurement of serum adiponectin and leptin concentrations has been performed as described previously (19; 20) . IL-6 plasma concentrations were measured by a high-sensitivity ELISA kit (Quantikine IL-6, R&D Systems, Oxford, UK). Insulin sensitivity was assessed with the euglycemichyperinsulinemic clamp method using a previously described protocol (21) . Glucose infusion rate (GIR) was calculated from the last 45 min of the clamp, during which 5 glucose infusion rate could be kept constant in order to achieve the target plasma glucose concentration of 5.5 (± 5%) mmol/L. Therefore, the duration of the clamp varied between individuals (range 120-200min). GIR was normalized to lean body mass. In premenopausal women, clamp studies were performed during the luteal phase of the menstrual cycle. All participants gave their written informed consent before taking part in the study. All investigations have been approved by the ethics committee of the University of Leipzig (363-10-13122010 and 017-12-230112) and were carried out in accordance with the Declaration of Helsinki.
Human IL-6 mRNA expression was measured by qRT-PCR using Assay-onDemand gene expression kit (Hs00985639_m1; Applied Biosystems, Darmstadt, Germany), and fluorescence was detected on an ABI PRISM 7000 Sequence Detector (Applied Biosystems). IL-6 mRNA expression was calculated relative to the mRNA expression of HPRT1 mRNA (Hs01003267_m1; Applied Biosystems).
Animals
Adipocyte-specific gp130 knockout mice (gp130 ∆adipo ) on a C57BL/6J background were generated by crossing gp130 floxed (gp130 F/F ) mice (22) to animals expressing the Cre recombinase controlled by the Adipoq promoter (AdipoqCre mice; purchased from
The Jackson Laboratory).
Six weeks-old male mice were fed ad libitum with standard rodent diet (chow) or high fat diet (HFD; D12331, Research Diets, New Brunswick, USA) for 12 weeks. HFD consisted of 58% of calories derived from fat, 28% from carbohydrate and 16% from protein. All protocols conformed to the Swiss animal protection laws and were approved by the Cantonal Veterinary Office in Zurich, Switzerland.
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Glucose clamp studies
Glucose clamp studies were performed as described (23 
Cell size determination
Cell size of isolated adipocytes was analyzed by a Multisizer™ 3 Coulter
Counter® as previously described (27) .
Blood sampling
Immediately after euthanasia abdominal cavity was opened and the portal vein exposed. It was punctured by a syringe (0.30mm (30G) x 8mm; BD, New Jersey, USA) and the blood was collected. Systemic blood was sampled after cardiac puncture using similar syringes. Blood was added to an Eppendorf tube with a final concentration of 5 mM EDTA. After centrifugation, plasma was stored at -80°C upon further processing.
Determination of plasma insulin, triglyceride and free fatty acids
Plasma triglyceride (TG) and free fatty acid (FFA) levels were determined as described elsewhere (28) . Plasma insulin levels were measured using an ELISA kit as described previously (29) .
Western blotting
Liver or adipose tissue samples were homogenized and Western blotting was performed as described previously (30) . The following primary antibodies were used:
anti-gp130, anti-SOCS3 (Santa Cruz Biotechnology, Dallas, TX, USA), anti-phospho p38, anti-phospho ERK, anti-ERK (Cell Signaling, Danvers, MA, USA) and anti-actin (Millipore, Billerica, MA, USA). Membranes were exposed in an Image Reader and analyzed with Image Analyzer (FujiFilm, Dielsdorf, Switzerland).
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RNA extraction and quantitative reverse transcription-PCR (RT-PCR)
Total RNA was extracted using RNeasy Lipid Tissue Mini Kit (Qiagen, Basel, Switzerland) and concentration was determined spectrophotometrically (Nanodrop 1000; Nanodrop Technologies, Boston, MA). 1 µg of RNA were reverse transcribed with Superscript III Reverse Transcriptase (Invitrogen, Basel, Switzerland) using random hexamer primer (Invitrogen). Taqman (Applied Biosystems, Rotkreuz, Switzerland) was used for real-time PCR amplification. The following PCR primers (Applied Biosystems)
were used: TNF-α Mm00443258_m1, IL-6 Mm00446190_m1, F4/80 Mm00802529_m1,
Mm00443579_m1. Relative gene expression was obtained after normalization to 18sRNA (Applied Biosystems), using the formula 2 -∆∆cp (31) .
Liver triglyceride and total lipid determination
Liver tissue (20-30mg) was homogenized in PBS and lipids were extracted in a chloroform-methanol (2:1) mixture. Total liver lipids were determined by a sulfophosphovanillin reaction as previously described (32) . Liver triglyceride levels were determined in 50 mg of liver tissue according to the method of Bligh and Dyer (33) and quantified with an enzymatic assay (Roche Diagnostics, Rotkreuz, Switzerland).
Histology
Liver tissues were fixed in 4% buffered formalin and embedded in paraffin.
Sections were cut and stained with hematoxylin and eosin.
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Data analysis
Statistical analyses were performed using Student's t test or ANOVA with
Newman-Keuls post-hoc test. In human studies, linear relationships were assessed by Spearman Rank correlation analyses. p-Values < 0.05 were considered significant.
Results
Similar weight gain and adipogenesis in adipocyte-specific gp130 knockout mice and control littermates
To investigate the role of IL-6-induced lipolysis in metabolic derangements in vivo, we generated adipocyte-specific gp130 knockout mice (gp130 ∆adipo ) using the crelox system. As controls, littermate mice with floxed gp130 but absent Cre-recombinase expression were used (gp130 F/F ). While we are aware of the fact that knockout of gp130 in adipocytes affects the signaling pathway of all members of the IL-6 cytokines, it still seems to be an adequate mouse model to investigate our hypothesis as the mIL-6R is not expressed in adipocytes (7), precluding cell-specific depletion of IL-6 signaling in adipocytes similar to liver-specific IL-6R knockout mice (13) . As expected, gp130 protein levels were highly reduced in isolated adipocytes of gp130 ∆adipo mice, decreased in white adipose tissue (WAT), which also contains non-adipocyte cell types, but unchanged in skeletal muscle and liver compared to control mice ( Figure 1A ). To induce obesity, 6
weeks old mice were either fed a control chow or a HFD for 12 weeks. As expected, HFD feeding increased body and fat pad weights, whereas lack of IL-6 cytokine signaling in adipocytes did not affect body weight or adipogenesis as assessed by fat pad weights and adipocyte size ( Figures 1B to 1F Figure 2C and 2D) confirming previous findings in adipocytes in vitro (15) . Ex vivo findings of reduced lipolysis in portally-drained mesenteric adipocytes were confirmed in vivo, as the obesity-induced increase in circulating FFA levels was blunted in portal but not systemic circulation of knockout mice ( Figures 2E and 2F ). Importantly and in contrast to lipolysis, gp130 depletion did not affect IL-6 mRNA expression in mesenteric WAT ( Figure 2G ), suggesting similar portal delivery of IL-6 to the liver in both genotypes.
In addition, there was no major change in transcript levels of the macrophage markers CD11b and F4/80 (34) (Fig. 2H) , suggesting similar macrophage content between both genotypes. Taken together, IL-6 cytokine signaling stimulates lipolysis of portally drained mesenteric but not of systemically drained epididymal fat. 
Reduced hepatic steatosis in HFD-fed gp130
Improved hepatic insulin sensitivity in HFD-fed gp130 ∆adipo mice
Steatosis is closely associated with liver insulin resistance that may be also affected by WAT lipolysis (39) . In this regard, increased portal delivery of FFA may induce liver insulin resistance via the accumulation of lipid metabolites and/or hepatic acetyl CoA or directly via activation of p38 MAPK (16; 36; 37; 42) . Indeed and as mentioned above, phosphorylation of p38 MAPK was decreased in livers of obese gp130 ∆adipo ( Figure 3A ). To assess hepatic insulin sensitivity, hyperinsulinemiceuglycemic clamp studies were performed. HFD-fed gp130 ∆adipo mice revealed significantly improved insulin sensitivity as determined by higher glucose infusion rate (GIR) during hyperinsulinemic-euglycemic clamp studies ( Figure 4A and Supplemental Figures 2A to 2C ). Insulin-induced suppression of endogenous glucose production (mainly reflecting hepatic glucose production) was significantly higher in HFD-fed gp130 ∆adipo compared to gp130 F/F mice ( Figure 4B ) indicating improved hepatic insulin sensitivity in knockout mice. In contrast, glucose uptake capacity into skeletal muscle 13 was not affected ( Figure 4C ). In addition, gp130 depletion had no impact on insulin's ability to suppress FFA release from isolated epididymal adipocytes ( Figure 4D ). In contrast and in support of depot-specific differences in adipocyte metabolism with regard to IL-6 cytokine action, insulin's ability to blunt lipolysis was significantly improved in mesenteric adipocytes isolated from obese knockout compared to control mice ( Figure   4E ).
Positive correlation of omental IL-6 expression with hepatic steatosis and insulin resistance in humans
Similar to observations in rodents, IL-6 expression was elevated in visceral/omental compared to subcutaneous fat depots in obese humans (43) .
Moreover, increased omental but not subcutaneous lipolysis was linked to obesityinduced fatty liver disease in morbidly obese humans (44) . To unravel whether IL-6-induced omental fat lipolysis may contribute to obesity-associated hepatic steatosis and insulin resistance, IL-6 mRNA expression was analyzed in adipose tissue of lean (n= 12, BMI 24.5±0.2 kg/m²) and overweight or obese (n=51, BMI 34.4±0.8 kg/m²) individuals and correlated to liver fat content. Basic clinical characteristics of these subjects are provided in Table 1 . Supporting previous findings (43), IL-6 mRNA was increased in omental, but not subcutanous adipose tissue of obese when compared to lean individuals ( Figure 5A ). Intriguingly, we found a significant positive correlation between omental (r=0.31; p<0.05) but not subcutaneous (r=0.09; p=0.49) IL-6 expression and hepatic steatosis ( Figure 5B and Supplemental Figure 3A ). In addition, glucose infusion rate (GIR) during hyperinsulinemic-euglycemic clamp studies revealed significant negative correlation to omental but not subcutaneous IL-6 mRNA expression ( Figure 5C 14 and Supplemental Figure 3B ). Of note, there was a significant correlation between liver fat content and clamp GIR (r=-0.53, p<0.001). These data support a role for omental in the development of obesity-associated hepatic steatosis as well as insulin resistance in humans.
Discussion
The present study suggests that IL-6 signaling-mediated lipolysis may be restricted to omental/mesenteric adipose tissue and that it contributes to hepatic insulin resistance and steatosis. Such notion is based on the following findings: i. lipolysis from mesenteric but not epididymidal adipose tissue is reduced in HFD-fed gp130 ∆adipo mice compared to control littermates; ii. gp130 depletion specifically in adipocytes reduced both HFD-induced hepatic insulin resistance and steatosis.
IL-6 plays complex roles in inflammation and metabolism having both beneficial and adverse properties. In support of detrimental effects of IL-6, it was very recently shown that IL-6 induces FFA release in obesity, thereby contributing to increased hepatic glucose production and, hence, hepatic insulin resistance (16) . Our findings presented herein would suggest that the IL-6 signaling-mediated increase in lipolysis is restricted to the portally drained mesenteric adipose tissue depot since depletion of gp130, the common signal transducer of IL-6, reduced FFA release only from isolated mesenteric but not epididymal adipocytes. As IL-6 is the gp130 cytokine with the bestknown lipolytic function (9) , such finding may be explained by an increased sensitivity of mesenteric adipocytes to IL-6-mediated lipolysis. However, IL-6-induced FFA release was only slightly elevated in mesenteric compared to epididymal adipocytes isolated from wild-type mice (1.25±0.14 fold in mesenteric vs. 1.12±0.02 fold in epididymal, p=0.4). Alternatively, a selective obesity-induced increase in IL-6 content of mesenteric WAT may be responsible for the observed difference (17; 18) . The later may be the result of unique endogenous properties of mesenteric WAT and/or depend on the close proximity to the gut leading to more pronounced inflammation in mesenteric/omental compared to other fat depots (35) . Along this line, the staphylococcal enterotoxin A (SEA) was reported to bind to gp130 in adipocytes thereby interfering with insulin sensitivity and lipolysis (45) . Interestingly, Staphylococcal spp. is detectable in gut microbiota and translocation of intestinal bacteria to mesenteric WAT was observed upon high fat feeding in mice (46; 47) . Clearly, further studies are needed to unravel a potential involvement of SEA in obesity-induced adipose tissue lipolysis.
Besides IL-6, other cytokines signaling via gp130 may have contributed to the observed phenotype. Of note, several IL-6 cytokines were shown to individually affect differentiation and adipogenesis rendering gp130 a potential therapeutic target to combat obesity and its associated diseases (9) . Accordingly, it was recently shown that blocking IL-6 trans-signaling using a soluble gp130Fc protein reduces obesity-induced infiltration of macrophages into adipose tissue (48) . We found herein that lack of IL-6 cytokine signaling in adipocytes had no impact on fat mass and adipocyte size. Such observation may suggest that IL-6 cytokine signaling does not affect adipogenesis.
However, Cre expression in our mouse model was under the control of the adiponectin promoter and, hence, only induced during late stages of adipocyte differentiation since it is located downstream of C/EBP (49). Thus, potential effects of individual IL-6 cytokines on early adipocyte differentiation (9) may not be reflected in gp130 ∆adipo mice.
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Chronically elevated circulating IL-6 levels were proposed to contribute to obesityassociated hepatic inflammation and insulin resistance in mice (11; 12) . In contrast, IL-6
was recently reported to reduce inflammation and to improve insulin sensitivity in liver (13) . Our findings may propose an indirect negative impact of IL-6 on hepatic insulin resistance and steatosis through induction of adipose tissue lipolysis mainly in mesenteric/omental fat depots. Accordingly, depletion of IL-6 cytokine signaling in adipocytes reduced portal FFA concentration and improved hepatic lipid accumulation as well as insulin resistance in mice. Moreover, omental (but not subcutaneous) IL-6 expression correlated with hepatic steatosis and insulin resistance in humans. Since it was recently shown that increased omental (but not subcutaneous) lipolysis was linked to obesity-induced fatty liver disease in morbidly obese humans (44) and that visceral lipolysis may contribute significantly to the portal delivery of FFA to the liver (50) our proposed mechanism may be conserved between species. Besides reduced lipolysis, lower intestinal absorption of FFA (35) or increased fatty acid uptake by adipocytes may have contributed to decreased portal FFA levels in HFD-fed gp130 ∆adipo mice. While our data suggest that increased mesenteric FFA release into the portal vein impairs liver metabolism, such direct link may be questioned (51) . Clearly, changed release of other non-FFA factors into portal and/or systemic circulation may have also contributed to the observed hepatic phenotype in obese gp130 ∆adipo mice.
In conclusion, the obesity-associated rise in mesenteric/omental adipose tissue IL-6 cytokine signaling promotes FFA release into the portal circulation inducing hepatic steatosis and/or insulin resistance. Hence, blocking IL-6 cytokine signaling in adipocytes may be a novel approach to blunt detrimental fat-liver crosstalk in obesity. To this end, 17 the development of cell-specific adeno-associated virus (AAV) vectors may be a promising tool in the future (52; 53). 
Figure Legends
